PolarityTE, Inc. (PTE)
| Market Cap | 57.89M |
| Revenue (ttm) | 14.17M |
| Net Income (ttm) | -37.74M |
| Shares Out | 80.60M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 279,252 |
| Open | 0.721 |
| Previous Close | 0.720 |
| Day's Range | 0.693 - 0.723 |
| 52-Week Range | 0.553 - 1.990 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 2.25 (+216.3%) |
| Est. Earnings Date | Nov 8, 2021 |
About PTE
PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or remova...
Financial Performance
In 2020, PolarityTE's revenue was $10.13 million, an increase of 79.16% compared to the previous year's $5.65 million. Losses were -$42.85 million, -53.67% less than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PolarityTE stock is "Buy." The 12-month stock price forecast is 2.25, which is an increase of 216.32% from the latest price.
News
Pomerantz Law Firm Announces the Filing of a Class Action Against PolarityTE, Inc. and Certain Officers - PTE
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its offi...
Down 18.2% in 4 Weeks, Here's Why PolarityTE, Inc. (PTE) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for PolarityTE, Inc. (PTE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analy...
PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthca...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwri...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PolarityTE, Inc. - PTE
NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE).
PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and ...
PolarityTE Stock Drops On FDA Clinical Hold On SkinTE Trial Application
The FDA has issued a clinical hold on PolarityTE Inc's (NASDAQ: PTE) SkinTE Investigational New Drug Application (IND) for chronic cutaneous ulcers. The FDA provided feedback on certain Chemistry, Manuf...
PTE Stock: The FDA News That Has Biotech Penny Stock PolarityTE Plunging Today
PolarityTE (PTE) stock is taking a beating on Tuesday after the biotechnology company got an update from the FDA on its IND. The post PTE Stock: The FDA News That Has Biotech Penny Stock PolarityTE Plun...
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding correspondence from ...
All You Need to Know About PolarityTE, Inc. (PTE) Rating Upgrade to Buy
PolarityTE, Inc. (PTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PolarityTE, Inc. (PTE) Reports Q2 Loss, Lags Revenue Estimates
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of 50.00% and -16.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PolarityTE Reports Second Quarter Financial Results and Provides Business Update
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial...
PolarityTE, Inc. (PTE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
PolarityTE, Inc. (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PolarityTE to Report Second Quarter Financial Results on August 12, 2021
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approxima...
PolarityTE's SkinTE Meets Primary, Secondary Endpoint Goals In Diabetic Foot Ulcer Trial
PolarityTE Inc (NASDAQ: PTE) has announced final data from a trial evaluating SkinTE plus standard of care (SOC) vs. SOC alone for Diabetic Foot Ulcers.
SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its inv...
PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) se...
PolarityTE Issues Statement About Potential Ticker Symbol Confusion
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is issuing the following statement: Based on investor inquiries, it has been brought to the attention of PolarityTE that there may be conf...
PolarityTE Receives Notice of Allowance for Chinese Patent
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent...
Is the Options Market Predicting a Spike in PolarityTE (PTE) Stock?
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
PolarityTE Stock Drops On Wider Than Expected Q1 Loss, SkinTE Transitions To BLA Pathway
PolarityTE Inc (NASDAQ: PTE) reported a Q1 EPS loss of $(0.24), missing the consensus of $(0.12) loss, but better than $(0.39) loss a year ago. Sales of $4.71 million increased 31% sequentially and over...
PolarityTE, Inc. (PTE) Reports Q1 Loss, Tops Revenue Estimates
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of 7.69% and 88.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
PolarityTE Reports First Quarter Results and Provides Business Update
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial...
Why PolarityTE (PTE) Might Surprise This Earnings Season
PolarityTE (PTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Market Update: The 10 Most Volatile Stocks Today
Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on In...
Why PolarityTE Shares Are Trading Higher On Monday
PolarityTE (NASDAQ: PTE) shares are trading higher after the company announced its Diabetic Foot Ulcers trial met its primary and secondary endpoints. In the company's multi-center randomized controlled...